Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 22, 2013 - Issue 3
Submit an article Journal homepage
337
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II – III invasive breast cancer: the OOTR-N001 study

Louis WC ChowOrganisation for Oncology and Translational Research, Unit A, 9/F, CNT Commercial Building, 302 Queen's Road Central, Hong Kong, China+852 2117 8011; +852 2117 0021; [email protected];UNIMED Medical Institute, Comprehensive Centre for Breast Diseases, Hong Kong, China
,
Stewart Y TungTuen Mun Hospital, Department of Clinical Oncology, Hong Kong, China
,
Ting-Ying NgTuen Mun Hospital, Department of Clinical Oncology, Hong Kong, China
,
Seock-Ah ImSeoul National University Hospital, Department of Internal Medicine, Seoul, Korea
,
Min-Hyuk LeeSoonchyunhang University Hospital, Department of Surgery, Seoul, Korea
,
Adrian YS YipOrganisation for Oncology and Translational Research, Unit A, 9/F, CNT Commercial Building, 302 Queen's Road Central, Hong Kong, China+852 2117 8011; +852 2117 0021; [email protected]
,
Masakazu ToiOrganisation for Oncology and Translational Research, Unit A, 9/F, CNT Commercial Building, 302 Queen's Road Central, Hong Kong, China+852 2117 8011; +852 2117 0021; [email protected];Kyoto University, Department of Surgery, Kyoto, Japan
&
Stefan GlückUniversity of Miami, Leonard M. Miller School of Medicine, Division of Hematology/Oncology, Miami, FL, USA
 show all
Pages 299-307 | Published online: 11 Feb 2013

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jieqing Li, Qiongyu Hao, Wei Cao, Jaydutt V Vadgama & Yong Wu. (2018) Celecoxib in breast cancer prevention and therapy. Cancer Management and Research 10, pages 4653-4667.
Read now

Articles from other publishers (15)

Amiya Das, Pallavi Agarwal, Gaurav Kumar Jain, Geeta Aggarwal, Viney Lather & Deepti Pandita. (2022) Repurposing Drugs as Novel Triple-negative Breast Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry 22:3, pages 515-550.
Crossref
Jiyeon Lee, Ji-Hyun Hwang, Harim Chun, Wonjin Woo, Sekyung Oh, Jungmin Choi & Lark Kyun Kim. (2021) PLEKHA8P1 Promotes Tumor Progression and Indicates Poor Prognosis of Liver Cancer. International Journal of Molecular Sciences 22:14, pages 7614.
Crossref
Masakazu Toi & Ravi Velaga. 2021. Translational Research in Breast Cancer. Translational Research in Breast Cancer 613 622 .
Ying Lu, Ling-Ling Liu, Shou-Sheng Liu, Zhi-Gang Fang, Yong Zou, Xu-Bin Deng, Zi-Jie Long, Quentin Liu & Dong-Jun Lin. (2016) Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. Journal of Translational Medicine 14:1.
Crossref
William P. Bozza, Yaqin Zhang, Kory Hallett, Leslie A. Rivera Rosado & Baolin Zhang. (2015) RhoGDI deficiency induces constitutive activation of Rho GTPases and COX-2 pathways in association with breast cancer progression. Oncotarget 6:32, pages 32723-32736.
Crossref
Laura W. Bowers & Linda A. deGraffenried. (2015) Targeting the COX-2 Pathway to Improve Therapeutic Response in the Obese Breast Cancer Patient Population. Current Pharmacology Reports 1:5, pages 336-345.
Crossref
Richard B. Schwab, Shumei Kato, Brian Crain, Minya Pu, Karen Messer, Noel Weidner, Sarah L. Blair, Anne M. Wallace, Dennis A. Carson & Barbara A. Parker. (2015) A window‐of‐opportunity biomarker study of etodolac in resectable breast cancer. Cancer Medicine 4:10, pages 1583-1588.
Crossref
Nadine Houédé & Philippe Pourquier. (2015) Targeting the genetic alterations of the PI3K–AKT–mTOR pathway: Its potential use in the treatment of bladder cancers. Pharmacology & Therapeutics 145, pages 1-18.
Crossref
Richard E. Kast, Georg Karpel-Massler & Marc-Eric Halatsch. (2014) CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget 5:18, pages 8052-8082.
Crossref
Nataliya Babyshkina, Elena Malinovskaya, Stanislav Patalyak, Olga Bragina, Natalia Tarabanovskaya, Artem Doroshenko, Elena Slonimskaya, Vladimir Perelmuter & Nadejda Cherdyntseva. (2014) Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. Medical Oncology 31:9.
Crossref
Rui-Jun Ju, Xue-Tao Li, Ji-Feng Shi, Xiu-Ying Li, Meng-Ge Sun, Fan Zeng, Jia Zhou, Lei Liu, Cheng-Xiang Zhang, Wei-Yu Zhao & Wan-Liang Lu. (2014) Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. Biomaterials 35:26, pages 7610-7621.
Crossref
Jiujiao Gao, Qiu Yan, Shuai Liu & Xuesong Yang. (2014) Knockdown of EpCAM Enhances the Chemosensitivity of Breast Cancer Cells to 5-fluorouracil by Downregulating the Antiapoptotic Factor Bcl-2. PLoS ONE 9:7, pages e102590.
Crossref
WENWEN SUI, YUEYING ZHANG, ZHAOPENG WANG, ZHAOXIA WANG, QING JIA, LICUN WU & WEIDONG ZHANG. (2014) Antitumor effect of a selective COX-2 inhibitor, celecoxib, may be attributed to angiogenesis inhibition through modulating the PTEN/PI3K/Akt/HIF-1 pathway in an H22 murine hepatocarcinoma model. Oncology Reports 31:5, pages 2252-2260.
Crossref
Yongmei Pan, Tiejun Cheng, Yanli Wang & Stephen H. Bryant. (2014) Pathway Analysis for Drug Repositioning Based on Public Database Mining. Journal of Chemical Information and Modeling 54:2, pages 407-418.
Crossref
Louis WC Chow, Wings TY Loo, Adrian YS Yip & Elizabeth LY Ng. (2018) Acceptable Cardiac Safety Profile of Neoadjuvant 5-Fluorouracil, Epirubicin, Cyclophosphamide and Celecoxib (FEC-C) for Breast Cancer: A Subanalysis of Biomarkers for Cardiac Injury. The International Journal of Biological Markers 28:1, pages 32-37.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.